Relationship between mediator release from human lung mast cells in vitro and in vivo
- PMID: 2409026
- DOI: 10.1159/000233752
Relationship between mediator release from human lung mast cells in vitro and in vivo
Abstract
There is now compelling evidence to incriminate bronchial mast cells in the pathogenesis of bronchoconstriction of allergic asthma. Human mast cells isolated from lung tissue or bronchoalveolar lavage release histamine and generate eicosanoids upon IgE-dependent activation. In this paper we present data that raise doubts about the significance of phospholipid methylation in IgE-dependent activation-secretion coupling and provide evidence that drugs such as 3-deazaadenosine inhibit mediator secretion by inhibiting phosphodiesterase, in addition to inhibiting putative methylation pathways. Activation of human mast cells and basophils also stimulates adenylate cyclase to increase levels of cyclic AMP, which, on the basis of pharmacological manipulation with purine nucleosides, we believe is involved in the progression of the secretory response. Human lung cells also generate both cyclo- and lipoxygenase products of arachidonate upon Ca++-dependent stimulation with complex interactions occurring between these pathways in the presence of the leukotriene inhibitor, Piriprost. The role of mast cells in the immediate airway response to inhaled allergens in asthma was demonstrated by showing an interaction between nonspecific bronchial reactivity and mast cell reactivity in predicting the airway response upon antigen inhalation. Further confirmation of this concept was obtained by showing an inverse relationship between the release of histamine and neutrophil chemotactic factor (NCF) into the circulation induced by antigen challenge, and nonspecific airway reactivity. The identification of significant increases in circulating mediators following antigen provocation of patients with seasonal asthma enabled the effects of drugs used in the treatment of asthma to be compared on airway calibre and mast cell mediator release. Sodium cromoglycate partially inhibited the airway and plasma histamine responses with antigen, but totally inhibited the increases in NCF. Salbutamol completely inhibited all responses, while ipratropium bromide, which produced the same bronchoconstriction as achieved with salbutamol, had no effect. The potent H1-antagonist astemizole partially inhibited bronchoconstriction without affecting histamine release. Antigen provocation produced a significant increase in circulating levels of the 13,14-dihydro-15-keto metabolite of PGF2 alpha which could originate from mast cell-derived PGD2. In both retrospective and prospective studies, a close relationship was shown between nonspecific bronchial reactivity and resting airway calibre in asthma.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Mediators of hypersensitivity and inflammatory cells in the pathogenesis of bronchial asthma.Eur J Respir Dis Suppl. 1983;129:1-44. Eur J Respir Dis Suppl. 1983. PMID: 6418559 Review.
-
The relationship between mast cell-mediator release and bronchial reactivity in allergic asthma.J Allergy Clin Immunol. 1987 Nov;80(5):703-11. doi: 10.1016/0091-6749(87)90291-0. J Allergy Clin Immunol. 1987. PMID: 2445803 Review.
-
Isoproterenol-induced inhibition of immunoglobulin E-mediated release of histamine and arachidonic acid metabolites from the human lung mast cell.J Pharmacol Exp Ther. 1988 Oct;247(1):209-17. J Pharmacol Exp Ther. 1988. PMID: 2459368
-
On the role of PGD2 metabolites as markers of mast cell activation in asthma.Acta Physiol Scand Suppl. 1999 Apr;644:1-74. Acta Physiol Scand Suppl. 1999. PMID: 10352758 Review.
-
Release of histamine and arachidonate from mouse mast cells induced by glycosylation-enhancing factor and bradykinin.J Immunol. 1985 Mar;134(3):1880-7. J Immunol. 1985. PMID: 2578523
Cited by
-
Effects of a cyclo-oxygenase inhibitor, flurbiprofen, and an H1 histamine receptor antagonist, terfenadine, alone and in combination on allergen induced immediate bronchoconstriction in man.Thorax. 1987 Dec;42(12):946-52. doi: 10.1136/thx.42.12.946. Thorax. 1987. PMID: 2894081 Free PMC article. Clinical Trial.
-
H1-antihistamines and calmodulin antagonists inhibit the ionophore A23187-induced eicosanoid formation by human leukocytes.Agents Actions. 1989 Mar;26(3-4):273-8. doi: 10.1007/BF01967290. Agents Actions. 1989. PMID: 2567567
-
The pathophysiology of bronchial asthma and targets for its drug treatment.Agents Actions. 1986 Jun;18(3-4):281-7. doi: 10.1007/BF01964985. Agents Actions. 1986. PMID: 2875629 No abstract available.
-
Mediator involvement in antigen-induced bronchospasm and microvascular leakage in the airways of ovalbumin sensitized Brown Norway rats.Br J Pharmacol. 2001 Jan;132(2):481-8. doi: 10.1038/sj.bjp.0703847. Br J Pharmacol. 2001. PMID: 11159698 Free PMC article.
-
Leukocyte activation following IgE dependent mechanisms in bronchial asthma.Clin Rev Allergy. 1989 Spring;7(1):49-72. doi: 10.1007/BF02914429. Clin Rev Allergy. 1989. PMID: 2655859 Review. No abstract available.